This month Maia & I cover a few highlights from the American Society for Clinical Oncology (ASCO) annual meeting that recently concluded in Chicago. I discuss a few locally advanced non-metastatic rectal cancer trial results, while Maia talks about the DESTINY CRC-02 and NeoCol trials. She ends her section with a study that compares genomic alterations between early-onset and late-onset colorectal cancer.
Here’s the link on the FightCRC website: